Tesamorelin is a synthetic 44-amino acid analogue of growth hormone-releasing hormone (GHRH), with a longer duration of action in the body. It stimulates the pituitary to release growth hormone, increasing insulin-like growth factor-1 (IGF-1) production. Elevated IGF-1 supports fat breakdown, glucose metabolism, and cell survival [1].
Originally approved to treat HIV-associated lipodystrophy, tesamorelin has been shown to significantly reduce visceral adipose tissue [1]. Emerging research is now exploring its broader therapeutic potential, including liver health, cardiometabolic risk, and neurological health.
Clinical trials consistently show that tesamorelin reduces visceral adipose tissue (VAT) in people with HIV and central adiposity. Across studies, about 70% of participants were considered “responders,” achieving at least an 8% VAT reduction within 26 weeks [2], [3].
Importantly, the benefits extended beyond fat volume: tesamorelin also improved fat quality, with significant increases in VAT density compared to placebo [2]. This shift suggests a move toward smaller, healthier adipocytes and a more favorable metabolic profile [2].
These effects were observed regardless of baseline fat levels. In a large phase III trial of 806 participants, most experienced meaningful VAT reductions [3].
A separate trial of 412 subjects found that tesamorelin produced a selective 1-kg reduction in visceral fat over six months, with little effect on subcutaneous or limb fat [4]. Participants also reported less distress about abdominal size [4].
Overall, tesamorelin demonstrates clinically significant, treatment-dependent benefits for both VAT quantity and quality, although gains tend to diminish after discontinuation [5].
Tesamorelin has shown consistent liver-related benefits, particularly in people with HIV. In one study, higher baseline VAT was associated with elevated liver enzymes (AST and ALT) [3].
Participants who responded to tesamorelin with significant VAT reduction also demonstrated improvements in AST and ALT. These hepatic benefits persisted even after treatment discontinuation despite partial VAT regain [3].
Randomized controlled trials corroborate this. In HIV-associated fatty liver disease, tesamorelin reduced liver fat and prevented fibrosis progression over 12 months [6].
Liver biopsies revealed upregulation of oxidative phosphorylation pathways, enhanced mitochondrial function, and downregulation of genes tied to inflammation, tissue repair, and cell proliferation—all processes linked to fibrosis and liver injury [6].
Importantly, tesamorelin also shifted gene expression toward patterns associated with a more favorable liver cancer prognosis [6].
A 12-month double-blind trial confirmed these findings, showing a 4.1% absolute and 37% relative reduction in hepatic fat fraction. By the study's end, 35% of the tesamorelin-treated participants achieved liver fat <5%, compared with only 4% of placebo participants [7].
In people with HIV and antiretroviral therapy-associated lipodystrophy, tesamorelin also improved lipid profiles, improving triglycerides and cholesterol ratios without impairing glucose tolerance [4].
Similar effects were seen in abdominally obese adults with reduced growth hormone (GH) secretion, where 12 months of therapy reduced VAT by 35 cm² while preserving subcutaneous fat [8].
This was accompanied by reductions in triglycerides, C-reactive protein, and carotid intima-media thickness, indicating improvements in systemic inflammation and cardiovascular risk.
IGF-1 levels rose significantly, confirming GH pathway activation, while glucose measures remained stable [8]. In type 2 diabetes, tesamorelin modestly improved lipid levels without impairing insulin sensitivity [9].
Additional findings suggest enhanced mitochondrial and muscle function, with improved phosphocreatine recovery after exercise [10]. Pooled phase III trial analyses confirm durable VAT reductions, lipid improvements, and better body image ratings [11].
Furthermore, reductions in excess visceral fat were linked to lower predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk, largely mediated by cholesterol improvements [12].
The natural age-related decline of GHRH, GH, and IGF-1 may contribute to age-related cognitive changes. This explains why tesamorelin also improves brain health.
Aside from improving neurological health through metabolic changes and immunomodulation, tesamorelin also positively affects neurotransmitter balance. In antiretroviral therapy-treated HIV patients, abdominal obesity was linked to neurocognitive impairment.
In a six-month trial, tesamorelin-treated participants achieved a significant waist circumference reduction and improvement in cognition [13].
In older adults and those with mild cognitive impairment (MCI), 20 weeks of tesamorelin treatment improved cognition and neurochemistry. The cognitive improvements corresponded with higher brain GABA (gamma-aminobutyric acid), increased N-acetyl-aspartyl-glutamate in the frontal cortex, and reduced myo-inositol in the posterior cingulate cortex [14].
In another trial enrolling 152 adults, 20 weeks of tesamorelin improved executive function and verbal memory, and was associated with a 117% IGF-1 increase, reduced body fat, and mild adverse events [15].
Other studies suggest GHRH and growth hormone-based therapies may promote peripheral nerve regeneration by supporting axonal growth, limiting muscle atrophy, and enhancing repair processes [16].
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Tesamorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.